Bull and Bear

Bull and Bear

Verdict: Watchlist - the balance-sheet discount is real, but the current evidence still shows a cash-rich producer converting scale into inventory, write-down risk, and weak cash quality rather than earnings. Bull has the cleaner valuation argument: consolidated cash exceeds market cap, reported debt is zero, and the stock sits far below its five-year average book multiple. Bear has the cleaner current-evidence argument: FY2025 ASP was below production cost, Q1 2026 sales collapsed despite production, and FY2025 positive CFO leaned on supplier-note financing. The decisive tension is unit economics versus sell-through: Daqo needs above-cost ASP and normalized shipments at the same time, not one without the other. A quarterly disclosure showing ASP above total cost, sales volume near production, no new inventory or asset charge, and positive CFO after notes payable normalizes would move this toward a long verdict.

Bull Case

Bull's price target is $41 over 18 months. The method is book-value reversion to the Numbers tab's 0.627x five-year mean P/B, rounded from the $40.8354 bull ADS value. Bull's thesis trigger is Q2-Q3 2026 earnings showing polysilicon ASP above the FY2025 $6.61/kg production cost with shipments rising toward production after Q1 2026 sales of 4,482 MT. The disconfirming signal is a Q3 2026 print with ASP below $6.61/kg and sales volume under 50% of production.

Bear Case

Bear's downside target is $13.00 over 12 months. The method is a 0.20x P/B liquidation-style book discount, using the Numbers tab bear case at $13.02 per ADS and the Technicals tab's $12.74 52-week low. Bear's primary trigger is Q2/Q3 2026 earnings showing production again far above sales plus another inventory or impairment charge. The cover signal is a quarterly disclosure showing ASP above total production cost, sales volume within 10% of production, and positive CFO after notes payable normalizes.

The Real Debate

Verdict

Verdict: Watchlist. Bear carries more weight today because the bull case depends on cash and book value becoming distributable earning power, while the current evidence still shows below-cost FY2025 unit economics, Q1 2026 sell-through collapse, negative FCF, and notes-payable-assisted CFO. The single most important tension is unit spread versus sell-through: Q1 2026 ASP nearly matched total cost, but sales were only 4,482 MT against 43,402 MT of production and the quarter still showed a $139.4M gross loss. Bull could still be right because Daqo has $1.94B of consolidated cash, zero reported debt, a low cash-cost position, and a stock trading at 0.291x book, so confirmed price discipline would make the equity look mispriced quickly. The condition that would change the verdict is a quarterly disclosure with ASP above total production cost, sales volume within 10% of production, no inventory or long-lived asset charge, and positive CFO after notes payable normalizes. Until that combination appears, the institutional verdict is to keep the name on watch rather than underwrite the $41 book-reversion case at face value.